Logo image
Serum growth factors in asbestosis patients
Journal article   Peer reviewed

Serum growth factors in asbestosis patients

Yongliang Li, Antti Karjalainen, Heikki Koskinen, Harri Vainio, Eero Pukkala, Kari Hemminki and Paul W. Brandt-Rauf
Biomarkers, v 14(1), pp 61-66
Feb 2009
PMID: 19283526

Abstract

Various growth factors, including platelet-derived growth factor (PDGF) and transforming growth factor (TGF)-β, have been implicated in the pathogenesis of asbestos-induced disease. PDGF and TGF-β levels were determined by enzyme-linked immunosorbent assays in the banked serum samples of a cohort of workers with asbestosis, and the relationships of the growth factor levels to the subsequent development of cancer and to the radiographic severity and progression of asbestosis in the cohort were examined. Serum levels of PDGF and TGF-β were found to be unrelated to the development of cancer, and serum levels of PDGF were found to be unrelated to the severity and progression of asbestosis. However, serum levels of TGF-β were found to be statistically significantly related to disease severity (p = 0.01), increasing approximately 2.4-fold from ILO radiographic category 0 to category 3, and they were marginally related to disease progression (p = 0.07), in multivariate analysis controlling for other contributory factors including cumulative asbestos exposure. This suggests that serum TGF-β may be a useful biomarker for asbestos-induced fibrotic disease.

Metrics

10 Record Views
5 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Biotechnology & Applied Microbiology
Toxicology
Logo image